The Food and Drug Administration (FDA or Agency) is providing interested persons with the opportunity to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of eight drug substances. These comments will be considered in preparing a response from the United States to the Expert Committee on Drug Dependence (ECDD) regarding the abuse liability and diversion of these drugs. The ECDD will use this information to consider whether to recommend that certain international restrictions be placed on these drug substances. This notice requesting comments is required by the Controlled Substances Act (CSA).
US Federal Register - FDA Notices · August 26, 2026
International Drug Scheduling; Request for Comments on Clobromazolam, Cychlorphine, Desalkylgidazepam, Ethylbromazolam, Etomethazene, Spirochlorphine, Etomidate, and Medetomidine
Original title: International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
FDA requests comments on abuse potential, medical usefulness, and trafficking of eight drug substances for international scheduling consideration.
Published by US Federal Register - FDA Notices. HealthSignal links to the original document; the summary above is extracted from the source text.